TREM2 protects from atherosclerosis by limiting necrotic core formation
Marie Piollet,Florentina Porsch,Giuseppe Rizzo,Frederieke Kapser,Dirk J J Schulz,Máté G Kiss,Kai Schlepckow,Estrella Morenas-Rodriguez,Mustafa Orkun Sen,Julius Gropper,Sourish Reddy Bandi,Sarah Schäfer,Tobias Krammer,Alexander M Leipold,Matthias Hoke,Mária Ozsvár-Kozma,Hannah Beneš,Martin Schillinger,Erich Minar,Melanie Roesch,Laura Göderle,Anastasiya Hladik,Sylvia Knapp,Marco Colonna,Rudolf Martini,Antoine-Emmanuel Saliba,Christian Haass,Alma Zernecke,Christoph J Binder,Clément Cochain
DOI: https://doi.org/10.1038/s44161-024-00429-9
Abstract:Atherosclerosis is a chronic disease of the vascular wall driven by lipid accumulation and inflammation in the intimal layer of arteries, and its main complications, myocardial infarction and stroke, are the leading cause of mortality worldwide [1], [2]. Recent studies have identified Triggering receptor expressed on myeloid cells 2 (TREM2), a lipid-sensing receptor regulating myeloid cell functions [3], to be highly expressed in macrophage foam cells in experimental and human atherosclerosis [4]. However, the role of TREM2 in atherosclerosis is not fully known. Here, we show that hematopoietic or global TREM2 deficiency increased, whereas TREM2 agonism decreased necrotic core formation in early atherosclerosis. We demonstrate that TREM2 is essential for the efferocytosis capacities of macrophages, and to the survival of lipid-laden macrophages, indicating a crucial role of TREM2 in maintaining the balance between foam cell death and clearance of dead cells in atherosclerotic lesions, thereby controlling plaque necrosis.